A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects with Essential Hypertension who are Inadequately Controlled on Nifedipine Gastrointestinal Therapeutic System Monotherapy
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2018
Price : $35 *
At a glance
- Drugs Candesartan cilexetil/nifedipine (Primary) ; Nifedipine
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Bayer HealthCare
- 01 Nov 2018 Trial has been discontinued in Italy
- 26 Jan 2017 Status changed from recruiting to completed.
- 12 Oct 2013 Planned End Date changed from 29 May 2013 to 2 Jul 2014 as reported by European Clinical Trials Database.